JAHA

Closed Loop Medicine Demonstrates Application of Novel Drug Plus Software Product for Personalized Treatment of Hypertension

Retrieved on: 
목요일, 2월 8, 2024
Medical Devices, Health, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Innovation, American College, Senior, Orthostatic hypertension, Medicine, Invention, Death, Amlodipine, Therapy, Disease, Drug intolerance, Patient, Cerebral edema, COVID, Triage, Trust, Hypertension, BP, Journal, American Heart Association, Journal of Human Hypertension, JAHA, Innovate UK, Blood pressure, Pharmaceutical industry

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).

Key Points: 
  • Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).
  • Hypertension is the leading preventable cause of morbidity and premature death worldwide.
  • High adherence rates were reported (both app usage and medication) and patient retention was exceptionally high with no discontinuations due to drug intolerance.
  • Dr. Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “These findings are invaluable in demonstrating the power of personalizing the dose of existing therapeutics in areas as widely impactful as hypertension.

Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association

Retrieved on: 
월요일, 11월 20, 2023
Other Science, Pharmaceutical, Research, Telemedicine, Virtual Medicine, Artificial Intelligence, Medical Devices, Hospitals, Genetics, Science, Technology, Clinical Trials, Medical Supplies, Cardiology, General Health, Biotechnology, Health, University, Education, Radiation, Security (finance), Entrepreneurship, Travel, Federal Medical Centres, Artificial intelligence, Cardiovascular disease, Patient, Assessment, Journal, PCR, Coronary artery disease, American Heart Association, CHD, Diagnosis, Validation, Intermountain Health, Methylation, Growth, Moyamoya disease, Hospital, Telehealth, Medical device, Medical imaging, JAHA

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA) , an official journal of the American Heart Association.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA) , an official journal of the American Heart Association.
  • The article entitled "The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease," unveils a significant leap in CHD diagnosis.
  • Furthermore, some of the tests are not sensitive to all forms of CHD and can be very costly.
  • As a result, millions of Americans do not receive adequate and potentially lifesaving cardiac care in a timely manner.

New Family Heart Foundation Study Reveals Systemic Underdiagnosis and Undertreatment of Homozygous Familial Hypercholesterolemia

Retrieved on: 
화요일, 5월 2, 2023
Health, Family, Consumer, Other Health, Other Philanthropy, Philanthropy, Other Science, Research, Parenting, Children, Genetics, Foundation, Science, Cardiology, Database, Registry, Pediatrics, American Heart Association, Stroke, Pediatrics (journal), Splenic infarction, FH, American Academy, LLT, Bangladesh Technical Education Board, Journal, Genetic disorder, Patient, Diagnosis, ASCVD, Moyamoya disease, Journal of the American Heart Association, JAHA, Disease, Dietary supplement

A new study from the Family Heart Foundation , a leading research and advocacy organization, showed the diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) is delayed, and often occurs after a heart attack or early atherosclerotic cardiovascular disease (ASCVD).

Key Points: 
  • A new study from the Family Heart Foundation , a leading research and advocacy organization, showed the diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) is delayed, and often occurs after a heart attack or early atherosclerotic cardiovascular disease (ASCVD).
  • HoFH is a rare disease and is the most severe form of the common inherited genetic disorder called familial hypercholesterolemia (FH).
  • “This Family Heart Foundation study demonstrates missed opportunities for HoFH diagnosis across the lifespan, with many adults in the U.S. still undiagnosed, leading to very real consequences from early heart attacks or strokes,” said Mary P. McGowan, M.D., chief medical officer, Family Heart Foundation, and co-author of the study.
  • The study examined the HoFH population in two proprietary Family Heart Foundation databases: CASCADE FH® Registry and the Family Heart Database™.

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention

Retrieved on: 
목요일, 3월 10, 2022
NASDAQ, Heart, JAHA, MI, American Heart Association, Professional corporation, Percutaneous, Risk, Percutaneous coronary intervention, Prior, PCI, CV, Infarction, Hospital, IPE, Angina, Blood, Journal, GLOBE, Journal of the American Heart Association, Patient, NNT, Stroke, Population, Myocardial infarction, History, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the publication of new REDUCE-IT data analysis that helps support the clinical benefits of icosapent ethyl (IPE) for patients who have received a percutaneous coronary intervention (PCI) and are at high risk for experiencing a stroke, heart attack, or fatal cardiovascular (CV) event.(1)

Key Points: 
  • This publication furthers the clinical evidence base for icosapent ethyl treatment in patients with prior PCI at risk of a recurrent CV event.
  • (1)
    There is evidence suggesting that patients who have a prior PCI are at a heightened risk of subsequent CV events compared with other patients with CV risk factors.
  • Treatment with Icosapent Ethyl to Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention - Insights from REDUCE-IT PCI.
  • Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.ii Significant cardiovascular risk remains after statin therapy.

Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American Heart Association Annual Meeting

Retrieved on: 
목요일, 10월 7, 2021
Journal of the American Heart Association, MESO, The Texas Heart Institute, Science, Heart, Private Securities Litigation Reform Act, III, Chief, Acute respiratory distress syndrome, Death, Stroke, Targeted molecular therapy for neuroblastoma, Foundation, MSB, Heart failure, SEC, MACE, Degenerative disease, Inflammation, American Heart Association, Physician, LinkedIn, SGLT2, Immune system, Twitter, Australian Securities Exchange, Journal, Technology, Incidence, Cardiology, AHA, JAHA, Patient, European Society of Cardiology, FDA, Mesoblast, Company, CHF, Forward-looking statement, New York Heart Association Functional Classification, GLOBE, NYHA, Risk, Intention, Baylor College of Medicine, Infarction, Mesenchyme, Prevalence, Arrest, Peer review, Pharmaceutical industry

The session will also feature late breaking results from two additional heart failure trials with SGLT-2 Inhibitors.

Key Points: 
  • The session will also feature late breaking results from two additional heart failure trials with SGLT-2 Inhibitors.
  • Heart failure affects approximately 6.5 million people in the US and 26 million people globally, with increasing prevalence and incidence.
  • The American Heart Association is the USs oldest and largest voluntary organization dedicated to fighting heart disease and stroke.
  • Mesoblast has completed Phase 3 trials of rexlemestrocel-L for advanced chronic heart failure and chronic low back pain.

Research Proves Wellframe Improves Patient Adherence to Cardiac Rehabilitation Programs

Retrieved on: 
화요일, 8월 31, 2021
Journal of the American Heart Association, Journal, Degenerative disease, Program, Coronary artery disease, Cardiac rehabilitation, Boston Medical Center, GLOBE, CDC, Research, JAHA, Medicare, American Heart, Death, Urban, Risk, Mortality, Partnership, Patient, Organization, CR, Outline, Woman, American Heart Association, MD, Medical device, Pharmaceutical industry

To address this health crisis, CR programs assess individual risk factors and outline a tailored health management, nutrition and exercise program accordingly.

Key Points: 
  • To address this health crisis, CR programs assess individual risk factors and outline a tailored health management, nutrition and exercise program accordingly.
  • This is especially important in a cardiac rehabilitation context, where many patients may have multiple concurrent conditions.
  • Cardiac rehabilitation programs are incredibly useful in reducing the mortality rate of heart disease up to 34%, but as little as 14% of eligible patients will participate or complete these programs.
  • Wellframe is helping to bring these programs to the 21st-century by efficiently, effectively, and proactively managing and improving health outcomes.

Afimmune's Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study

Retrieved on: 
목요일, 8월 26, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Company, Eicosapentaenoic acid, Hypertriglyceridemia, Lists of diseases, COVID, Severe acute respiratory syndrome coronavirus 2, Viral load, Dyslipidemia, Drug discovery, JAHA, Journal of the American Heart Association, EPA, Multimedia, Safety, Risk, Patient, CEO, Cardiovascular disease, NASH, Type 2 diabetes, Triglyceride, Fatty liver disease, COVID-19, American Heart Association, Pharmaceutical industry

Epeleuton has already been shown to have anti-inflammatory and positive metabolic effects in clinical trials in patients (phase 2) conducted by the Company.

Key Points: 
  • Epeleuton has already been shown to have anti-inflammatory and positive metabolic effects in clinical trials in patients (phase 2) conducted by the Company.
  • At the higher Epeleuton dose, as early as day 1 and on the peak of viral load on day 2, there were no detectable viral titres in the throat.
  • Epeleuton also decreased the extent and severity of inflammatory and histopathological changes in both the upper and lower respiratory tracts in a dose-dependent manner.
  • The potency of Epeleuton on viral load, replication, and histopathological improvement on both the upper and lower respiratory tract underline the therapeutic potential of Epeleuton in COVID-19 and possibly in long COVID.

MFDS Greenlights VUNO Med®-DeepCARS™, AI Medical Device for Cardiac Arrest Prediction

Retrieved on: 
화요일, 8월 24, 2021
Incidence, Journal, Critical Care Medicine (journal), Asan Medical Center, Adoption, EMR, JAHA, Vital signs, Emergency medicine, Cardiac arrest, Ministry of Food and Drug Safety, Hospital, Multimedia, Clinical trial, Survival rate, Ministry, MFDS, Resuscitation, Mortality, Risk, Patient, High-dependency unit, American Heart Association, CCM, Korean Journal of Anesthesiology, Medical device

SEOUL, South Korea, Aug. 24, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO MedDeepCARS, an AI medical device for cardiac arrest prediction through vital signs.

Key Points: 
  • SEOUL, South Korea, Aug. 24, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO MedDeepCARS, an AI medical device for cardiac arrest prediction through vital signs.
  • VUNO MedDeepCARS is a breakthrough AI-driven medical device that analyzes the potential risk of cardiac arrest using four primary vital signs:
    These data points are collected from the electronic medical record (EMR) of hospitalized patients.
  • It has been shown to provide reliable early cardiac arrest prediction which can enable medical practitioners to mount a rapid and effective response.
  • In September 2020, the device was designated as a "Breakthrough Medical Device" by the MFDS in recognition of both its technological merit and its innovative efficacy in the clinical settings.